ClinicalTrials.gg
Not yet recruitingNCT07659704CLEVER-SLEUpdated Oct 29, 2026

CD19-Directed CAR-T Cell Therapy in Refractory Systemic Lupus Erythematosus

A Phase 1/2 interventional study of Autologous CD19-Directed CAR-T Cells Manufactured at Ribeirão Preto Blood Center in Lupus Erythematosus, Systemic, sponsored by University of Sao Paulo. Not yet recruiting at 2 sites in Brazil. Open to participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2026-10-29.

Sponsored by University of Sao Paulo · Phase 1/2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
16
Allocation
Not applicable
Ages
18 Years to 50 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 96 studies in Lupus Erythematosus, Systemic with a site in Brazil — 19 open to participants now, 37 under way, 18 of them phase 3. Lupus Erythematosus, Systemic · Brazil.

Planned enrollment
92nd of 93
16 · median 292
Started
2026
with 11 others
Phase 1/2
Only one
of the 96
Primary completion
2027-10
later than 14 of 36 live
Registered
95th of 96
by date
Lead sponsor
5 of 96
University of Sao Paulo

Among the 96 studies in Lupus Erythematosus, Systemic with a site in Brazil, this one is the 92nd largest by planned enrollment of the 93 interventional ones that give a count, is one of 12 that started in 2026, is the only one in phase 1/2, reaches primary completion later than 14 of the 36 other live ones, and was the 95th registered.

Lupus Erythematosus, Systemic

1,211 studies on the registry are indexed under Lupus Erythematosus, Systemic; 406 are open to participants now.

Browse Lupus Erythematosus, Systemic studies →

Open to participants now

19 of the 96 studies in Lupus Erythematosus, Systemic with a site in Brazil are open now. Recruiting first, the newest first:

13 more — sign in →

All 19 open studies →

A study can be open while its sites in Brazil have not opened yet or have stopped. Only those recruiting at a site in Brazil →

Who these studies take

Of the 284 Lupus Erythematosus, Systemic studies recruiting now, 94 (33%) set no upper age limit and 160 (56%) stop at 75 or younger; 54 take children under 18; 32 take healthy volunteers.

This study: 18 Years to 50 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 96 studies in Lupus Erythematosus, Systemic with a site in Brazil, or all of them as a file.
02

Study summary

Systemic lupus erythematosus (SLE) is a chronic autoimmune disease in which the immune system mistakenly attacks the body's own tissues and organs. The disease can affect the skin, joints, kidneys, blood cells, brain, and other organs, leading to significant health problems and reduced quality of life. Although several treatments are available, some patients continue to have active disease despite receiving standard therapies.

Recent research has shown that B cells, a type of immune cell, play a central role in the development and persistence of SLE. CD19-directed chimeric antigen receptor T-cell (CAR-T) therapy is an innovative treatment that uses a patient's own immune cells, genetically modified to recognize and eliminate B cells. This approach has already shown remarkable success in certain blood cancers and has recently produced encouraging results in patients with severe autoimmune diseases, including SLE.

The CLEVER-SLE study is a Phase I/II clinical trial designed to evaluate the safety and potential effectiveness of CD19-directed CAR-T cell therapy produced at Ribeirao Preto Blood Bank in patients with SLE who have not responded adequately to conventional treatments. Participants will undergo the collection of their own immune cells, which will be modified in a specialized laboratory to produce CAR-T cells. After receiving preparatory chemotherapy, participants will receive a single intravenous infusion of these CAR-T cells.

The main goal of this study is to evaluate the safety of this treatment. Researchers will also assess its effects on disease activity, symptoms, organ involvement, medication requirements, immune system markers, and the duration of clinical responses. The study aims to determine whether CD19-directed CAR-T cell therapy can provide a new treatment option for patients with refractory SLE and contribute to the development of CAR-T therapies for autoimmune diseases.

Read the detailed description

Systemic lupus erythematosus (SLE) is a chronic, multisystem autoimmune disease characterized by loss of immune tolerance, production of pathogenic autoantibodies, and immune-mediated tissue injury. The disease can affect virtually any organ system, including the skin, joints, kidneys, hematologic system, cardiovascular system, and central nervous system. Despite major advances in the understanding of disease pathogenesis and the availability of immunosuppressive and biologic therapies, many patients continue to experience persistent disease activity, recurrent flares, progressive organ damage, reduced quality of life, and increased mortality.

B lymphocytes play a central role in the pathogenesis of SLE. Beyond their ability to differentiate into antibody-producing plasma cells, B cells contribute to disease development through antigen presentation, cytokine production, and maintenance of autoreactive immune responses. The persistence of autoreactive B-cell populations is believed to be a key driver of chronic disease activity and treatment resistance.

Several therapeutic strategies targeting B cells have been developed for SLE, including anti-CD20 monoclonal antibodies and inhibitors of B-cell survival pathways. Although these approaches have improved outcomes for many patients, a substantial proportion of individuals fail to achieve sustained remission. One potential limitation of antibody-based therapies is their inability to completely eliminate autoreactive B-cell populations residing within inflamed tissues and specialized immune niches. In contrast, CD19-directed CAR-T cells are living immune effectors capable of expanding in vivo, trafficking to affected tissues, and mediating deep depletion of B cells not only in the peripheral blood but also within sites of ongoing autoimmune inflammation. This broader and more profound tissue-level B-cell depletion may contribute to more durable disease control and potentially restore immune tolerance. In addition, existing therapies often require continuous administration and may be associated with cumulative toxicities, incomplete disease control, or relapse after treatment discontinuation.

CD19-directed chimeric antigen receptor T-cell (CAR-T) therapy represents a novel therapeutic strategy that enables a patient's own T lymphocytes to recognize and eliminate CD19-expressing B cells. This approach has demonstrated unprecedented efficacy in B-cell malignancies and has transformed the treatment landscape of several hematologic cancers. More recently, emerging clinical evidence has suggested that deep B-cell depletion induced by CD19-directed CAR-T cells may also be capable of resetting abnormal immune responses in autoimmune diseases.

Early clinical experiences in patients with severe refractory autoimmune diseases, including systemic lupus erythematosus, have reported rapid and profound reductions in disease activity, sustained clinical remissions, normalization of serological markers, and significant reductions in the need for immunosuppressive medications. These findings have generated considerable interest in the potential application of CAR-T cell therapy beyond oncology and have established a strong scientific rationale for further investigation in autoimmune disorders.

The CAR-T product evaluated in this study consists of autologous T lymphocytes genetically modified to express a chimeric antigen receptor directed against CD19. The product is manufactured at the Ribeirão Preto Blood Center (Hemocentro de Ribeirão Preto), one of the leading academic cell therapy centers in Brazil. This manufacturing platform has previously demonstrated feasibility, safety, and clinical activity in patients with hematologic malignancies and serves as the foundation for the present investigation.

The CLEVER-SLE study was developed to evaluate the use of CD19-directed CAR-T cell therapy manufactured at the Ribeirão Preto Blood Center in patients with refractory systemic lupus erythematosus. The study seeks to expand current knowledge regarding the safety profile and therapeutic potential of CAR-T cells in autoimmune diseases while generating clinical evidence to support the development of advanced cellular therapies for patients with severe disease who have limited treatment options.

By investigating a strategy capable of directly targeting the cellular drivers of autoimmunity, this study aims to contribute to the development of transformative therapies that may achieve sustained disease control and improve long-term outcomes for patients with refractory SLE.

03

Conditions studied

  • Lupus Erythematosus, Systemic

Keywords

  • Systemic Lupus Erythematosus
  • SLE
  • Refractory Systemic Lupus Erythematosus
  • Lupus Nephritis
  • CAR-T Cell Therapy
  • CD19-Directed CAR-T Cells
  • CD19
  • Chimeric Antigen Receptor T Cells
  • B Cell Depletion
  • B Lymphocytes
  • Autoimmune Diseases
  • Cellular Therapy
  • Advanced Therapy Medicinal Products
  • Immune Reconstitution
  • Autologous CAR-T Cells
04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults aged 18 to 50 years, inclusive.
  • Diagnosis of systemic lupus erythematosus (SLE) according to the 2019 ACR/EULAR classification criteria.
  • Active disease at screening, defined as SLEDAI-2K ≥4 and Physician Global Assessment (PGA) ≥0.5.
  • Inadequate response, intolerance, or to and at least two of the following therapies: azathioprine, mycophenolate mofetil, cyclophosphamide, methotrexate, belimumab, rituximab, or tacrolimus.
  • Adequate organ function, including:

    • Hepatic function: and ALT ≤3× (ULN); total ≤2× ULN (participants with documented Gilbert syndrome are eligible).
    • Hematologic function: neutrophils ≥1,000/mm³; ≥8 g/dL without transfusion within 14 days; lymphocytes ≥500/mm³; ≥20,000/mm³ without transfusion within 14 days.
    • Renal function: estimated ≥30 mL/min ().
    • Cardiac function: ≥40%.
    • Pulmonary function: oxygen saturation ≥92% on room air.
  • Women of must agree to use highly effective during study participation and for 12 months after CAR-T cell infusion.
  • Male participants must agree to use barrier contraception during study participation and for 12 months after CAR-T cell infusion.
  • Ability to understand and provide written .

Exclusion criteria

Exclusion Criteria:

  • Severe pulmonary hypertension (estimated pulmonary artery systolic pressure >50 mmHg).
  • Requirement for systemic anticoagulation at screening.
  • cardiovascular disease, including Class III/IV heart failure, myocardial infarction, unstable arrhythmias, or unstable angina within the previous 6 months.
  • Active neurological disease (stroke, epilepsy, or neurodegenerative disorders) within the previous 12 months.
  • History of within 2 years prior to screening, except for adequately treated non-melanoma skin cancer, cervical carcinoma in situ, localized prostate cancer, ductal carcinoma in situ of the breast, or stage I uterine cancer.
  • Previous or suspected hemophagocytic lymphohistiocytosis/macrophage activation syndrome.
  • Active or uncontrolled bacterial, viral, fungal, or other infection.
  • Active infection or detectable HBV DNA.
  • Active infection or detectable HCV RNA.
  • (HIV) infection.
  • Pregnancy, breastfeeding, or plans to become pregnant during the study or within 12 months after CAR-T cell infusion.
  • Major surgery within 4 weeks prior to screening.
  • Administration of a within 4 weeks prior to screening.
  • Prior or autologous hematopoietic stem cell transplantation or prior solid organ transplantation.
  • Inability or unwillingness to comply with study procedures and follow-up requirements.
  • Any medical condition that, in the investigator's judgment, could compromise participant safety or interfere with study assessments.
Terms in these criteria, in plain language(21)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
16 participants (estimated)

Study arms

  • Experimental
    Autologous CD19-Directed CAR-T Cells

    Participants with refractory systemic lupus erythematosus will undergo leukapheresis for the manufacture of autologous CD19-directed CAR-T cells, followed by lymphodepleting chemotherapy and a single intravenous infusion of the CAR-T cell product.

    Biological: Autologous CD19-Directed CAR-T Cells Manufactured at Ribeirão Preto Blood Center

Interventions

  • BiologicalAutologous CD19-Directed CAR-T Cells Manufactured at Ribeirão Preto Blood Center

    Autologous CD19-directed chimeric antigen receptor T (CAR-T) cells developed and manufactured at the Ribeirão Preto Blood Center (Hemocentro de Ribeirão Preto, Brazil). T lymphocytes collected by leukapheresis are genetically modified ex vivo using a lentiviral vector to express a CD19-specific chimeric antigen receptor and subsequently expanded under Good Manufacturing Practice (GMP) conditions. Following standard lymphodepleting chemotherapy, participants receive a single intravenous infusion of the autologous CAR-T cell product. The therapy is intended to achieve deep and sustained depletion of CD19-positive B cells implicated in the pathogenesis of systemic lupus erythematosus.

06

What researchers measure

Primary outcomes

  1. Incidence and Severity of Cytokine Release Syndrome (CRS) and Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS)

    Incidence and maximum grade of CRS and ICANS following infusion of autologous CD19-directed CAR-T cells, assessed according to ASTCT consensus criteria.

    Time frame: 30 days after CAR-T cell infusion

Secondary outcomes

  1. Incidence of Grade ≥3 Cytopenias

    Incidence of grade ≥3 anemia, neutropenia, lymphopenia, and thrombocytopenia according to CTCAE v6.0.

    Time frame: Up to 90 days after CAR-T cell infusion

  2. Time to Hematologic Recovery

    Time to resolution of cytopenias to grade \<1.

    Time frame: Up to 12 months after CAR-T cell infusion

  3. Incidence and Severity of Infections

    Cumulative incidence and severity of infections

    Time frame: Up to 12 months after CAR-T cell infusion

  4. Incidence of Serious Infections

    Incidence of grade ≥3 infections according to CTCAE v6.0

    Time frame: Up to 12 months after CAR-T cell infusion

  5. Changes in Serum Immunoglobulin Levels

    Absolute and relative changes in serum IgG, IgA, and IgM concentrations compared with baseline

    Time frame: Baseline, Day 30, Day 90, Day 180, and Day 360

  6. Incidence of Other CAR-T Cell-Associated Toxicities

    Incidence and severity of coagulopathy, immune effector cell-associated hemophagocytic syndrome (IEC-HS), cytomegalovirus reactivation, and local immune effector cell-associated toxicity syndrome (LICATS)

    Time frame: Up to 12 months after CAR-T cell infusion

  7. Deep Remission Rate

    Percentage of participants achieving deep remission, defined as clinical SLEDAI-2K=0 (allowing isolated serological activity), Physician Global Assessment (PGA) ≤0.5, and no requirement for additional immunosuppressants, biologics, small molecules, or corticosteroids after CAR-T cell therapy.

    Time frame: 6 months after CAR-T cell infusion

  8. SRI-4 Response Rate

    Percentage of participants achieving an SRI-4 response, defined as a ≥4-point reduction in SLEDAI-2K score, no new BILAG A score and no more than one new BILAG B score, and no worsening in PGA (increase \<0.3 points)

    Time frame: 6 months after CAR-T cell infusion

  9. Lupus Low Disease Activity State (LLDAS) Achievement Rate

    Percentage of participants achieving LLDAS criteria

    Time frame: 6 and 12 months after CAR-T cell infusion

  10. DORIS Remission Rate

    Percentage of participants achieving Definitions Of Remission In SLE (DORIS) criteria

    Time frame: 6 and 12 months after CAR-T cell infusion

  11. Renal Response Rate

    Among participants with active lupus nephritis (proteinuria ≥500 mg/24 hours at baseline), percentage achieving complete renal response or partial renal response

    Time frame: 6 and 12 months after CAR-T cell infusion

  12. Cutaneous Lupus Response Rate

    Among participants with baseline CLASI-Activity score ≥10, percentage achieving CLASI-50 response, defined as ≥50% reduction in CLASI-Activity score from baseline.

    Time frame: 6 and 12 months after CAR-T cell infusion

  13. Articular Response Rate

    Among participants with ≥6 active arthritic joints at baseline, percentage achieving at least 50% reduction in the number of active joints

    Time frame: 6 and 12 months after CAR-T cell infusion

  14. Anti-dsDNA Serologic Response

    Percentage of participants achieving negative anti-double-stranded DNA antibody titers (negative or ≤1:10)

    Time frame: 6 and 12 months after CAR-T cell infusion

  15. Corticosteroid and Immunosuppressant-Free Remission

    Percentage of participants not receiving corticosteroids or immunosuppressive medications

    Time frame: 6 and 12 months after CAR-T cell infusion

Other outcomes

  1. Lymphocyte Subpopulation Kinetics

    Longitudinal assessment of B-cell, T-cell, and NK-cell populations in peripheral blood following CD19-directed CAR-T cell therapy

    Time frame: Screening, pre-lymphodepletion, Day 0, Day 7, Day 17, Day 24, Day 30, Day 60, Day 90, Day 180, and Day 360

  2. CAR-T Cell Expansion, Persistence, and Immunophenotype

    Assessment of circulating CAR-T cell levels and immunophenotypic characteristics following infusion

    Time frame: Pre-lymphodepletion, Day 3, Day 7, Day 10, Day 17, Day 24, Day 30, Day 60, Day 90, Day 180, and Day 360

  3. Inflammatory Cytokine Kinetics

    Longitudinal assessment of circulating inflammatory cytokine levels

    Time frame: Pre-lymphodepletion, Day 3, Day 7, Day 10, Day 17, Day 24, Day 30, Day 60, Day 90, Day 180, and Day 360

  4. Complement Recovery Kinetics

    Changes in serum complement C3 and C4 levels following treatment

    Time frame: Screening, pre-lymphodepletion, Day 30, Day 60, Day 90, Day 180, and Day 360

  5. Vaccine Antibody Titers

    Changes in antibody titers against measles and diphtheria-tetanus vaccination antigens

    Time frame: Pre-lymphodepletion, Day 30, Day 60, Day 90, Day 180, and Day 360

  6. NETosis Biomarkers

    Changes in peripheral blood markers associated with neutrophil extracellular trap (NET) formation and NETosis

    Time frame: Screening, Day 30, Day 60, Day 90, Day 180, and Day 360

07

Study locations

2 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2026; primary completion for Oct 2027, 12 months later.

Of 38 phase 1/2 interventional studies under Lupus Erythematosus, Systemic, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 60. This study's planned 12 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 15, 2026
First posted
Jun 22, 2026
StartEst.
Oct 1, 2026
Primary completionEst.
Oct 1, 2027
CompletionEst.
Oct 1, 2028
Last update
Oct 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date and responsible party
1 update, last Oct 29, 2026
Show all 1 update
  1. Oct 29, 2026
    Minor edits only
    + 2 other changes: verification date and responsible party

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07659704
Collaborators
Regional Blood Center of Ribeirao Preto
Responsible party
Diego Villa Clé (Principal Investigator, University of Sao Paulo) — Principal investigator
First posted
Jun 22, 2026
Start date
Oct 1, 2026 (estimated)
Primary completion
Oct 1, 2027 (estimated)
Completion
Oct 1, 2028 (estimated)
Last update
Oct 29, 2026

Study contacts

Diego V. Clé, MD, MBA, PhD
Contact
terapia@hemocentro.fmrp.usp.br
+55 16 21019300
Maria Carolina Oliveira Rodrigues, MD, PhD
Contact
mcarolor@usp.br

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion